| Diagnosis and Treatment of Periodontal Disease in Patients With AML (NCT04530695) | Masonic Cancer Center, University of Minnesota | 2022-05-01 |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (NCT04904588) | Center for International Blood and Marrow Transplant Research | 2021-09-30 |
| MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies (NCT04762875) | Ensoma | 2021-06-16 |
| Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome (NCT05263271) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2021-04-01 |
| A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia (NCT04806659) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2020-08-04 |
| Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) (NCT04278768) | Curis, Inc. | 2020-07-06 |
| Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia (NCT04172844) | Medical College of Wisconsin | 2020-01-13 |
| GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies (NCT03214666) | GT Biopharma, Inc. | 2020-01-01 |
| Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy (NCT04014764) | Notable Labs | 2019-12-15 |
| FT516 in Subjects With Advanced Hematologic Malignancies (NCT04023071) | Fate Therapeutics | 2019-10-04 |
| Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation (NCT03755414) | Washington University School of Medicine | 2019-09-04 |
| CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia (NCT03904251) | Jonsson Comprehensive Cancer Center | 2019-07-18 |
| Bisantrene for Relapsed /Refractory AML (NCT03820908) | Sheba Medical Center | 2019-07-18 |
| A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS (NCT03059615) | Immune System Key Ltd | 2018-10-25 |
| Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients (NCT03679650) | Beth Israel Deaconess Medical Center | 2018-10-11 |
| Resiliency in Older Adults Undergoing Bone Marrow Transplant (NCT04188678) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-09-28 |
| Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS (NCT03459859) | Justin Watts, MD | 2018-05-21 |
| CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR (NCT03152526) | Miltenyi Biotec B.V. & Co. KG | 2017-10-18 |
| Medium Dose of Cytarabine and Mitoxantrone (NCT04024241) | Shenzhen People's Hospital | 2017-09-01 |
| Epigenetic Reprogramming in Relapse/Refractory AML (NCT03263936) | Therapeutic Advances in Childhood Leukemia Consortium | 2017-07-11 |
| DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission (NCT03059485) | Beth Israel Deaconess Medical Center | 2017-06-01 |
| Allo HSCT Using RIC for Hematological Diseases (NCT02661035) | Masonic Cancer Center, University of Minnesota | 2017-03-09 |
| Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies (NCT02991898) | Masonic Cancer Center, University of Minnesota | 2017-02-16 |
| Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101) (NCT02773732) | University of Florida | 2016-12-16 |
| Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine (NCT02996773) | University of Arizona | 2016-11-29 |
| CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML (NCT02944162) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2016-10-01 |
| PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies (NCT02730312) | Xencor, Inc. | 2016-08-01 |
| Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (NCT02665065) | Actinium Pharmaceuticals | 2016-06-01 |
| Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation (NCT02719574) | Forma Therapeutics, Inc. | 2016-04-30 |
| MCLA-117 in Acute Myelogenous Leukemia (NCT03038230) | Merus B.V. | 2016-04-01 |
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies (NCT02639559) | Washington University School of Medicine | 2016-03-31 |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis (NCT02593123) | Virginia Commonwealth University | 2015-11-04 |
| Reduced Intensity Conditioning Transplant Using Haploidentical Donors (NCT02581007) | Northside Hospital, Inc. | 2015-10-26 |
| MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients (NCT02395822) | Masonic Cancer Center, University of Minnesota | 2015-10-01 |
| Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS (NCT02576301) | Mateon Therapeutics | 2015-10-01 |
| Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies (NCT02543879) | Forma Therapeutics, Inc. | 2015-09-01 |
| iCare for Cancer Patients (NCT02435550) | University of Florida | 2015-06-26 |
| Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation (NCT02458235) | University of California, San Francisco | 2015-06-02 |
| Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS (NCT02477787) | Asan Medical Center | 2015-06-01 |
| Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML) (NCT02323113) | Calithera Biosciences, Inc | 2015-03-09 |
| Study of TCP-ATRA for Adult Patients With AML and MDS (NCT02273102) | University of Miami | 2015-03-02 |
| Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation (NCT01483274) | University of Louisville | 2015-03-01 |
| Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies (NCT02338479) | Center for International Blood and Marrow Transplant Research | 2015-03-01 |
| A Pilot RCT of the PRISM Intervention for AYAs With Cancer (NCT02340884) | Seattle Children's Hospital | 2015-01-30 |
| Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML (NCT02255162) | Massachusetts General Hospital | 2015-01-01 |
| A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia (NCT02287233) | AbbVie | 2014-12-31 |
| A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML (NCT02326584) | Seagen Inc. | 2014-12-01 |
| Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) (NCT02319369) | Daiichi Sankyo | 2014-11-25 |
| Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes (NCT02296242) | BioMed Valley Discoveries, Inc | 2014-11-01 |
| Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) (NCT02203773) | AbbVie | 2014-10-06 |
| A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS (NCT02267863) | Aptose Biosciences Inc. | 2014-10-01 |
| Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients (NCT02109744) | University of Rochester | 2014-03-01 |
| AHN-12 Biodistribution in Advanced Leukemia (NCT01207076) | Masonic Cancer Center, University of Minnesota | 2013-12-01 |
| Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. (NCT02017457) | Carlos Graux, MD, PhD | 2013-12-01 |
| Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML) (NCT01397799) | Kinex Pharmaceuticals Inc. | 2013-12-01 |
| Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation (NCT01634217) | Masonic Cancer Center, University of Minnesota | 2013-11-08 |
| A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) (NCT01994837) | AbbVie | 2013-11-01 |
| CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission (NCT01639456) | Masonic Cancer Center, University of Minnesota | 2013-10-01 |
| P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies (NCT01854567) | Mesoblast, Ltd. | 2013-08-01 |
| A Safety Study of SGN-CD33A in AML Patients (NCT01902329) | Seagen Inc. | 2013-07-01 |
| Brentuximab Vedotin + Re-induction Chemotherapy for AML (NCT01830777) | Massachusetts General Hospital | 2013-05-01 |
| A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor (NCT01696461) | Center for International Blood and Marrow Transplant Research | 2013-05-01 |
| Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older (NCT01814826) | Millennium Pharmaceuticals, Inc. | 2013-04-10 |
| Human Placental-Derived Stem Cell Transplantation (NCT01586455) | New York Medical College | 2013-04-01 |
| Alisertib for Acute Myeloid Leukemia (NCT01779843) | Massachusetts General Hospital | 2013-04-01 |
| Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia (NCT01842672) | New York Medical College | 2013-03-01 |
| Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant (NCT01744223) | Bellicum Pharmaceuticals | 2013-03-01 |
| Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation (NCT01795378) | Asan Medical Center | 2013-02-01 |
| Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome (NCT01795924) | Biosuccess Biotech Co., Ltd. | 2013-01-01 |
| Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia (NCT01736943) | Joseph Tuscano | 2012-12-19 |
| Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis (NCT01749111) | Hospital Israelita Albert Einstein | 2012-12-01 |
| Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies (NCT01745913) | Weill Medical College of Cornell University | 2012-10-26 |
| Lenalidomide Plus Chemotherapy for AML (NCT01681537) | Massachusetts General Hospital | 2012-09-01 |
| Double Cord Versus Haploidentical (BMT CTN 1101) (NCT01597778) | Medical College of Wisconsin | 2012-06-01 |
| MRI Assessment of Leukemia Response to Therapy (NCT01537159) | OHSU Knight Cancer Institute | 2012-05-01 |
| A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia (NCT01358734) | Celgene | 2012-04-27 |
| The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q). (NCT01556477) | Nordic MDS Group | 2012-03-01 |
| A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives (NCT01532635) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-03-01 |
| Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell (NCT01660607) | Stanford University | 2012-02-09 |
| SCT Plus Immune Therapy in Average Risk AML/MDS (NCT02117297) | New York Medical College | 2012-01-12 |
| Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course (NCT00967512) | Eleos, Inc. | 2012-01-01 |
| Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation (NCT01491958) | Ohio State University Comprehensive Cancer Center | 2011-12-10 |
| Reduced Intensity Double Umbilical Cord Blood Transplantation (NCT01408563) | Massachusetts General Hospital | 2011-12-01 |
| A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia (NCT01486784) | Abramson Cancer Center at Penn Medicine | 2011-11-01 |
| Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match (NCT01500161) | Texas Oncology Cancer Center | 2011-11-01 |
| T-Cell Depleted Double UCB for Refractory AML (NCT01464359) | Masonic Cancer Center, University of Minnesota | 2011-10-01 |
| Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) (NCT01385423) | Masonic Cancer Center, University of Minnesota | 2011-09-01 |
| Selecting a Favorable KIR Donor in Unrelated HCT for AML (NCT01288222) | Masonic Cancer Center, University of Minnesota | 2011-06-01 |
| Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation (NCT01338987) | National Cancer Institute (NCI) | 2011-04-19 |
| Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (NCT00892190) | University of Pittsburgh | 2011-04-01 |
| TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation (NCT01300611) | Tarix Pharmaceuticals | 2011-01-01 |
| Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations (NCT00943943) | M.D. Anderson Cancer Center | 2010-10-29 |
| Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years (NCT01193400) | PETHEMA Foundation | 2010-09-01 |
| First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers (NCT01120457) | Bristol-Myers Squibb | 2010-08-01 |
| Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed Acute Myelogenous Leukemia (AML) (NCT02662920) | Wake Forest University Health Sciences | 2010-08-01 |
| Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL (NCT01187810) | South Plains Oncology Consortium | 2010-08-01 |
| Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML) (NCT01160354) | M.D. Anderson Cancer Center | 2010-08-01 |
| Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation (NCT01366612) | Hackensack Meridian Health | 2010-06-16 |
| Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias (NCT01149915) | Threshold Pharmaceuticals | 2010-06-01 |
| HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies (NCT01119066) | Memorial Sloan Kettering Cancer Center | 2010-05-03 |